Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antispike Gel for Adhesion Prevention in Appendicitis
NCT06365632Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Countries
- 1
- Modality
- Nanoparticles
- Drugs
- Antispike
- Conditions
- Abdominal Adhesions
01
Overview
Phase 2, randomised, single-blind trial of Antispike in Abdominal Adhesions (2 arms). Primary endpoint: Number of patients with acute phlegmonous appendicitis cured at 3 weeks. Started Mar 2025; status: active, not recruiting.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Antispike Group
Appendectomy + Antispike gel
Control Group
Appendectomy alone
03
Who it enrols
Adult patients (18-65) with acute phlegmonous appendicitis requiring surgery and having medium/high risk of abdominal adhesions. Excludes patients with severe concomitant diseases, cancer, or requiring steroid therapy.
04
Endpoints
Primary
Number of patients with acute phlegmonous appendicitis cured
Secondary
Absence of signs of adhesions
Beyond the preview
Go deeper on NCT06365632.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365632.